High Free Cash Flow Stocks
TBPH is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
THERAVANCE BIOPHARMA INC (TBPH) Stock Price & Overview
NASDAQ:TBPH • KYG8807B1068
Current stock price
16.1 USD
+0.08 (+0.5%)
At close:
16.1 USD
0 (0%)
After Hours:
The current stock price of TBPH is 16.1 USD. Today TBPH is up by 0.5%. In the past month the price increased by 18.64%. In the past year, price increased by 91.67%.
TBPH Key Statistics
52-Week Range8.315 - 21.03
Current TBPH stock price positioned within its 52-week range.
1-Month Range13.29 - 16.5
Current TBPH stock price positioned within its 1-month range.
- Market Cap
- 815.787M
- P/E
- N/A
- Fwd P/E
- 16.70
- EPS (TTM)
- -0.53
- Dividend Yield
- N/A
TBPH Stock Performance
Today
+0.5%
1 Week
+6.76%
1 Month
+18.64%
3 Months
-15.44%
Longer-term
6 Months +15.08%
1 Year +91.67%
2 Years +90.76%
3 Years +48.66%
5 Years -18.44%
10 Years -22.41%
TBPH Stock Chart
TBPH Stock Screens
TBPH currently appears in the following ChartMill screener lists.
Fastest Growing Stocks
TBPH is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
Revenue Growth Leaders
TBPH is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
TBPH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TBPH. When comparing the yearly performance of all stocks, TBPH is one of the better performing stocks in the market, outperforming 87.3% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TBPH Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TBPH. While TBPH has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TBPH Earnings
On March 19, 2026 TBPH reported an EPS of 0.21 and a revenue of 45.89M. The company missed EPS expectations (-83.12% surprise) and missed revenue expectations (-23.1% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS Reported$0.21
Revenue Reported45.891M
EPS Surprise -83.12%
Revenue Surprise -23.10%
TBPH Forecast & Estimates
13 analysts have analysed TBPH and the average price target is 16.49 USD. This implies a price increase of 2.42% is expected in the next year compared to the current price of 16.1.
For the next year, analysts expect an EPS growth of 281.87% and a revenue growth -4.42% for TBPH
Analysts
Analysts76.92
Price Target16.49 (2.42%)
EPS Next Y281.87%
Revenue Next Year-4.42%
TBPH Groups
Sector & Classification
TBPH Financial Highlights
Over the last trailing twelve months TBPH reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS increased by 51.38% compared to the year before.
Income Statements
Revenue(TTM)107.46M
Net Income(TTM)29.34M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 36.53% | ||
| ROA | 7.06% | ||
| ROE | 12.61% | ||
| Debt/Equity | 0.14 |
Chartmill High Growth Momentum
EPS Q2Q%167.74%
Sales Q2Q%144.7%
EPS 1Y (TTM)51.38%
Revenue 1Y (TTM)66.92%
TBPH Ownership
Ownership
Inst Owners99.38%
Shares50.67M
Float48.67M
Ins Owners3.96%
Short Float %10.58%
Short Ratio7.77
TBPH Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.52 | 874.551B | ||
| JNJ | JOHNSON & JOHNSON | 20.69 | 580.403B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.788B | ||
| PFE | PFIZER INC | 9.32 | 158.307B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.37 | 120.824B | ||
| ZTS | ZOETIS INC | 16.71 | 49.921B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.16 | 27.297B | ||
| VTRS | VIATRIS INC | 5.35 | 15.44B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.69 | 11.345B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.682B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.421B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.091B | ||
| CORT | CORCEPT THERAPEUTICS INC | 49.44 | 4.345B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TBPH
Company Profile
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Company Info
IPO: 2014-05-16
THERAVANCE BIOPHARMA INC
Ugland House, South Church Street
GEORGE TOWN GRAND CAYMAN KY1-1104 KY
CEO: Rick E Winningham
Employees: 97
Phone: 16508086000
THERAVANCE BIOPHARMA INC / TBPH FAQ
What does TBPH do?
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
What is the current price of TBPH stock?
The current stock price of TBPH is 16.1 USD. The price increased by 0.5% in the last trading session.
What is the dividend status of THERAVANCE BIOPHARMA INC?
TBPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of TBPH stock?
TBPH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the GICS sector and industry of TBPH stock?
THERAVANCE BIOPHARMA INC (TBPH) operates in the Health Care sector and the Pharmaceuticals industry.
What is the employee count for TBPH stock?
THERAVANCE BIOPHARMA INC (TBPH) currently has 97 employees.
What is the next earnings date for TBPH stock?
THERAVANCE BIOPHARMA INC (TBPH) will report earnings on 2026-05-06.